Ventyx Biosciences Holds Three Immunology Targets
Wednesday, March 24, 2021
Encinitas-based Ventyx Biosciences, a clinical-stage biotech company developing oral therapeutics for autoimmune disease, has landed a $114 million equity financing to advance its pipeline of immunology programs...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know